Adenosine A2a receptor antagonists attenuate striatal adaptations following dopamine depletion

Neurobiology of Disease

Volumn 45, Issue 1, 2012, Pages 409-416

  Peterson, Jayms D ^a   Goldberg, Joshua A ^a   Surmeier, D James ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

A2a; Adenosine; Cholinergic interneuron; D 2; Dopamine; Medium spiny neuron; Parkinson's disease; Patch clamp; Spine; Striatopallidal; Two photon laser scanning microscopy

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; DOPAMINE; DOPAMINE 2 RECEPTOR;

ADAPTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATTENUATION; BRAIN ELECTROPHYSIOLOGY; BRAIN SLICE; CELL TYPE; CHOLINERGIC NERVE CELL; CONTROLLED STUDY; CORPUS STRIATUM; DENDRITIC SPINE; MOUSE; NERVE CELL EXCITABILITY; NERVE PROJECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SYNAPTIC POTENTIAL;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; CORPUS STRIATUM; DENDRITES; DOPAMINE; MICE; NEURONS; PYRIMIDINES; RECEPTOR, ADENOSINE A2A; TRIAZOLES;

EID: 81955164816     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.08.030     Document Type: Article

References (56)

1. Albin R.L., et al. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989, 12:366-375.
2. Ballion B., et al. D2 receptor stimulation, but not D1, restores striatal equilibrium in a rat model of Parkinsonism. Neurobiol. Dis. 2009, 35:376-384.
3. Bernard V., et al. Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes. J. Neurosci. 1992, 12:3591-3600.
4. Bourne J.N., et al. Warmer preparation of hippocampal slices prevents synapse proliferation that might obscure LTP-related structural plasticity. Neuropharmacology 2007, 52:55-59.
5. Calabresi P., et al. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain 1993, 116(Pt 2):433-452.
6. Calabresi P., et al. Activation of M1-like muscarinic receptors is required for the induction of corticostriatal LTP. Neuropharmacology 1999, 38:323-326.
7. Canals M., et al. Homodimerization of adenosine A2A receptors: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J. Neurochem. 2004, 88:726-734.
8. Day M., et al. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat. Neurosci. 2006, 9:251-259.
9. Day M., et al. Differential excitability and modulation of striatal medium spiny neuron dendrites. J. Neurosci. 2008, 28:11603-11614.
10. Deutch A.Y., et al. Striatal plasticity and medium spiny neuron dendritic remodeling in parkinsonism. Parkinsonism Relat. Disord. 2007, 13(Suppl 3):S251-S258.
11. Ding J., et al. RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion. Nat. Neurosci. 2006, 9:832-842.
12. Ding J., et al. Corticostriatal and thalamostriatal synapses have distinctive properties. J. Neurosci. 2008, 28:6483-6492.
13. Ding J.B., et al. Thalamic gating of corticostriatal signaling by cholinergic interneurons. Neuron 2010, 67:294-307.
14. Flajolet M., et al. FGF acts as a co-transmitter through adenosine A(2A) receptor to regulate synaptic plasticity. Nat. Neurosci. 2008, 11:1402-1409.
15. Flavell S.W., et al. Activity-dependent regulation of MEF2 transcription factors suppresses excitatory synapse number. Science 2006, 311:1008-1012.
16. Fuxe K., et al. Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function. J. Mol. Neurosci. 2005, 26:209-220.
17. Fuxe K., et al. Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. Physiol. Behav. 2007, 92:210-217.
18. Gerfen C.R., Surmeier D.J. Modulation of striatal projection systems by dopamine. Annu. Rev. Neurosci. 2011, 34:441-466.
19. Harvey C.D., Svoboda K. Locally dynamic synaptic learning rules in pyramidal neuron dendrites. Nature 2007, 450:1195-1200.
20. Hauser R.A., Schwarzschild M.A. Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience. Drugs Aging 2005, 22:471-482.
21. 2+ influx by D2 dopamine and A2A adenosine receptors. Nat. Neurosci. 2010, 13:958-966.
22. Higley M.J., et al. Cholinergic modulation of multivesicular release regulates striatal synaptic potency and integration. Nat. Neurosci. 2009, 12:1121-1128.
23. Hoffman D.A., Johnston D. Downregulation of transient K+ channels in dendrites of hippocampal CA1 pyramidal neurons by activation of PKA and PKC. J. Neurosci. 1998, 18:3521-3528.
24. Ingham C.A., et al. Morphological changes in the rat neostriatum after unilateral 6-hydroxydopamine injections into the nigrostriatal pathway. Exp. Brain Res. 1993, 93:17-27.
25. Jenner P. A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD. Neurology 2003, 61:S32-S38.
26. Jenner P. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease. Curr. Opin. Neurol. 2003, 16(Suppl 1):S3-S7.
27. Kravitz A.V., et al. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 2010, 466:622-626.
28. Kreitzer A.C., Malenka R.C. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 2007, 445:643-647.
29. Kurokawa M., et al. Adenosine A2a receptor-mediated modulation of striatal acetylcholine release in vivo. J. Neurochem. 1996, 66:1882-1888.
30. Malenka R.C., Bear M.F. LTP and LTD: an embarrassment of riches. Neuron 2004, 44:5-21.
31. Mallet N., et al. Cortical inputs and GABA interneurons imbalance projection neurons in the striatum of parkinsonian rats. J. Neurosci. 2006, 26:3875-3884.
32. Matsuzaki M., et al. Structural basis of long-term potentiation in single dendritic spines. Nature 2004, 429:761-766.
33. Medvedev N.I., et al. The N-methyl-d-aspartate receptor antagonist CPP alters synapse and spine structure and impairs long-term potentiation and long-term depression induced morphological plasticity in dentate gyrus of the awake rat. Neuroscience 2010, 165:1170-1181.
34. Morelli M., et al. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Prog. Neurobiol. 2007, 83:293-309.
35. 2+ channels is dependent on a Shank-binding domain. J. Neurosci. 2005, 25:1050-1062.
36. Pinna A., et al. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug. Neuropharmacology 2010, 58:613-623.
37. Pisani A., et al. Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci. 2007, 30:545-553.
38. Preston Z., et al. Adenosine receptor expression and function in rat striatal cholinergic interneurons. Br. J. Pharmacol. 2000, 130:886-890.
39. Salmi P., et al. Adenosine-dopamine interactions revealed in knockout mice. J. Mol. Neurosci. 2005, 26:239-244.
40. Schiffmann S.N., et al. A2A receptor and striatal cellular functions: regulation of gene expression, currents, and synaptic transmission. Neurology 2003, 61:S24-S29.
41. Shalizi A., et al. A calcium-regulated MEF2 sumoylation switch controls postsynaptic differentiation. Science 2006, 311:1012-1017.
42. Shen W., et al. Cholinergic suppression of KCNQ channel currents enhances excitability of striatal medium spiny neurons. J. Neurosci. 2005, 25:7449-7458.
43. Shen W., et al. Cholinergic modulation of Kir2 channels selectively elevates dendritic excitability in striatopallidal neurons. Nat. Neurosci. 2007, 10:1458-1466.
44. Shen W., et al. Dichotomous dopaminergic control of striatal synaptic plasticity. Science 2008, 321:848-851.
45. Shiozaki S., et al. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berl) 1999, 147:90-95.
46. Smith Y., et al. The thalamostriatal system: a highly specific network of the basal ganglia circuitry. Trends Neurosci. 2004, 27:520-527.
47. 2+) channels in rat striatal cholinergic interneurons. J. Neurophysiol. 2000, 83:322-332.
48. Surmeier D.J., et al. Dopamine and synaptic plasticity in dorsal striatal circuits controlling action selection. Curr. Opin. Neurobiol. 2009, 19:621-628.
49. Svenningsson P., et al. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog. Neurobiol. 1999, 59:355-396.
50. Taverna S., et al. Recurrent collateral connections of striatal medium spiny neurons are disrupted in models of Parkinson's disease. J. Neurosci. 2008, 28:5504-5512.
51. Tian X., et al. MEF-2 regulates activity-dependent spine loss in striatopallidal medium spiny neurons. Mol. Cell. Neurosci. 2010, 44:94-108.
52. Tozzi A., et al. The distinct role of medium spiny neurons and cholinergic interneurons in the D/AA receptor interaction in the striatum: implications for Parkinson's disease. J. Neurosci. 2011, 31:1850-1862.
53. Turrigiano G. Homeostatic signaling: the positive side of negative feedback. Curr. Opin. Neurobiol. 2007, 17:318-324.
54. Wang Z., et al. Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. Neuron 2006, 50:443-452.
55. Xu-Friedman M.A., Regehr W.G. Probing fundamental aspects of synaptic transmission with strontium. J. Neurosci. 2000, 20:4414-4422.
56. 2+ currents in rat neostriatal cholinergic interneurons through a fast, membrane-delimited, G-protein pathway. J. Neurosci. 1996, 16:2592-2604.